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AbstrACt
Objectives To assess the feasibility and acceptability of 
a community pharmacy lifestyle intervention to improve 
physical activity and cardiovascular health of men with 
prostate cancer. To refine the intervention.
Design Phase II feasibility study of a complex 
intervention.
setting Nine community pharmacies in the UK.
Intervention Community pharmacy teams were trained 
to deliver a health assessment including fitness, strength 
and anthropometric measures. A computer algorithm 
generated a personalised lifestyle prescription for a home-
based programme accompanied by supporting resources. 
The health assessment was repeated 12 weeks later and 
support phone calls were provided at weeks 1 and 6.
Participants 116 men who completed treatment for 
prostate cancer.
Outcome measures The feasibility and acceptability of 
the intervention and the delivery model were assessed by 
evaluating study processes (rate of participant recruitment, 
consent, retention and adverse events), by analysing 
delivery data and semi-structured interviews with 
participants and by focus groups with pharmacy teams. 
Physical activity (measured with accelerometry at baseline, 
3 and 6 months) and patient reported outcomes (activation, 
dietary intake and quality of life) were evaluated. Change 
in physical activity was used to inform the sample size 
calculations for a future trial.
results Out of 403 invited men, 172 (43%) responded 
and 116 (29%) participated. Of these, 99 (85%) 
completed the intervention and 88 (76%) completed the 
6-month follow-up (attrition 24%). Certain components 
of the intervention were feasible and acceptable (eg, 
community pharmacy delivery), while others were more 
challenging (eg, fitness assessment) and will be refined 
for future studies. By 3 months, moderate to vigorous 
physical activity increased on average by 34 min (95% CI 
6 to 62, p=0.018), but this was not sustained over 
6 months.
Conclusions The community pharmacy intervention was 
feasible and acceptable. Results are encouraging and 
warrant a definitive trial to assess the effectiveness of the 
refined intervention.
IntrODuCtIOn
The number of men living with and beyond 
a prostate cancer diagnosis in the UK is 
increasing. It is predicted that by 2020 there 
will be over 400 000 prostate cancer survivors 
(1.3% of the population).1 Prostate cancer 
and its treatment have been shown to nega-
tively affect men’s physical2 and psycholog-
ical health,3 leading to an impaired quality 
of life.4–7 Therefore, mitigating the conse-
quences of cancer and its treatment is an 
important target for lifestyle interventions.
There is a growing body of evidence that 
lifestyle advice, including exercise and diet, 
can improve men’s quality of life and symp-
toms related to prostate cancer or its treat-
ment.8–11 Exercise has been shown to reduce 
hormone therapy-related fatigue12 and 
improve cardiovascular health.13 This is of 
strengths and limitations of this study
 ► This is the first study to assess the feasibility and 
acceptability of a community pharmacy lifestyle in-
tervention for men living with and beyond prostate 
cancer.
 ► A mixed method design included intervention de-
livery data, objective accelerometry, subjective 
outcome measures and qualitative data that will be 
used to refine the intervention.
 ► The nine community pharmacies were drawn from 
three different commercial business models (inde-
pendent as well as mid-size and large nationwide 
community pharmacy chains).
 ► The intervention has the potential for testing at scale 
because it is hosted by a web-based system used by 
more than 26 000 different providers in the UK.
 ► This feasibility study did not test randomisation of 
participants. This will require further user involve-
ment to explore feasibility and acceptability prior to 
a definitive trial.
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particular importance given the potential increased risk of 
cardiovascular disease associated with androgen depriva-
tion therapy (ADT) as a treatment for prostate cancer.14 15 
Furthermore, an exercise programme of 12 weeks for 
men starting ADT is recommended by the National Insti-
tute for Health and Care Excellence (NICE).16 Lifestyle 
interventions also provide survivorship benefits, with 
increased physical activity pretreatment and post-treat-
ment being associated with lower recurrence rates and 
less advanced prostate disease.17–19 The wider benefits 
of lifestyle interventions after cancer are improvements 
in metabolic health and treatment-related symptoms.20 
Potential barriers to the delivery of NICE guidelines in 
secondary care have been well documented21–23 and 
include attitudes of healthcare professionals, safety 
concerns and issues with the hospital environment, which 
means that few men receive lifestyle interventions.21 24 25
Primary care plays a clear and important role in 
supportive care during and after treatment,26 and for men 
with stable prostate cancer, NICE recommends hospital 
discharge and follow-up in primary care.16 Improved access 
to local cancer services in the community has been advo-
cated by the ‘National Health Service (NHS) 2010–2015: 
from good to great’ report.27 After their discharge, men 
have ongoing healthcare needs that require monitoring 
and support.28 29 Community pharmacies are well placed 
to deliver this care due to easy access and availability of 
professional expertise. This includes consultation skills 
and clinical knowledge regarding management of long-
term conditions and side-effects of medications including 
ADT. They currently deliver services such as medication 
use reviews, NHS Health Checks, diet and exercise advice, 
alcohol and smoking cessation.30 The role of community 
pharmacies is rapidly evolving in response to the health-
care demands of an ageing population, with multiple 
long-term conditions including cancer.31 Examples of 
health promotion and lifestyle interventions include the 
Healthy Living Pharmacy framework32 and NHS services 
such as influenza vaccination.33
The aim of this phase II study was to assess the feasibility 
and acceptability of a community pharmacy lifestyle inter-
vention to improve physical activity and cardiovascular 
health of men with prostate cancer. This is innovative 
research, and to our knowledge, the first study to develop 
and test a lifestyle intervention in a community pharmacy 
setting for men living with and beyond prostate cancer 
diagnosis. In prostate cancer, lifestyle interventions have 
been shown to reduce side-effects of ADT10 11 34 and to 
decrease risk of cardiovascular comorbidity.35 36 In a feasi-
bility study, Bourke et al showed short-term improvements 
in exercise and dietary behaviour due to a supervised 
exercise programme combined with dietary advice.37 
A primary care walking programme with older adults 
showed improvement in step counts which resulted in 
health benefits.38
A novel delivery approach via community pharmacies 
is presented here. The study is aligned with the vision of 
the Royal Pharmaceutical Society of Great Britain (2017), 
which is for the pharmacy workforce to develop more 
patient-centred roles and to expand primary care services 
into cancer follow-ups.39 This is also advocated by the 
NHS and NICE.16 40 41 The development and evaluation 
of this intervention were guided by the Medical Research 
Council's complex intervention framework.42 The evalua-
tion of the feasibility and acceptability included an assess-
ment of the delivery model (via community pharmacy), 
participant recruitment, consent and retention rates, and 
acceptability of the outcome measures. This study also 
provided preliminary evidence of the intervention effi-
cacy, and enabled an assessment of the effect size change 
in the primary outcome to inform a future randomised 
controlled trial (RCT).
MethODs
setting and selection of community pharmacies
The intervention was piloted in Portsmouth, UK home 
to the original Healthy Leaving Pharmacy (HLP) initia-
tive.32 HLP provides health promotion and self-care hubs 
in the Portsmouth region and other areas. The health 
status of the population in Portsmouth falls below that of 
the national average, with higher deprivation and lower 
life expectancy (7.9 years lower for men).32 Portsmouth 
also provided both urban and semi-rural localities for 
testing the intervention.
The community pharmacy lifestyle intervention was 
delivered by nine community pharmacies between June 
2016 and April 2017. The nine community pharmacies 
were recruited based on location (proximity to the cancer 
centre and spread across the locality) and commercial 
business model. They were drawn from three different 
commercial business models, including independent 
community pharmacy, mid-size nationwide community 
pharmacy limited company (>500 pharmacies) and large 
nationwide pharmacy limited company (>1500 pharma-
cies). Pharmacy teams were identified and consented to 
their participation in the study. This included participa-
tion in the mandatory training.
recruitment and participants
This was a non-randomised, single-group feasibility study 
and all participants received the intervention. Men from 
the Portsmouth area, with non-metastatic prostate cancer 
who completed their cancer treatment a minimum of 
3 months before (6 months for brachytherapy) were 
identified from one NHS Trust. Detailed participant 
screening, uptake and withdrawal data were collected and 
analysed to assess the feasibility and acceptability of the 
recruitment process.
Men were invited to participate by a letter from their 
Consultant and asked to respond to the University of Surrey 
research team. Those men who contacted the research 
team were further screened for eligibility before discussing 
participation in the study. Eligibility criteria included at 
least one of three cardiovascular risk factors: overweight or 
obese (BMI ≥25), and/or on active ADT and/or diagnosed 
 o
n
 12 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025114 on 11 June 2019. Downloaded from 
3Lemanska A, et al. BMJ Open 2019;9:e025114. doi:10.1136/bmjopen-2018-025114
Open access
hypertension. Men who were already physically active were 
excluded because the focus of this intervention was on those 
with more need. The definition by the UK’s Chief Medical 
Officer (CMO) of a minimum 150 min of moderate physical 
activity or a minimum of 75 min of vigorous physical activity 
per week in 10 or more minute bouts43 was used. Men, 
who on an initial screening, reported physical activity that 
exceeded CMO guidelines (eg, football, cycling or running 
for more than 3 hours a week) were excluded. In addition, 
men with an underlying medical condition that would limit 
their capacity to respond to advice about diet and physical 
activity were also excluded. All participants provided written 
consent. Figure 1 shows a flowchart detailing study time 
points and data collection activities and figure 2 the partici-
pant consort diagram.
Sample size for this feasibility study was 113 men (including 
an estimated 25% attrition) to detect a 22% difference in 
moderate to vigorous physical activity (MVPA) with 90% 
power, and two-tailed significance level of 5%. This was 
informed by a lifestyle intervention conducted by Harris et 
al44 who reported a 22% (95% CI 36 to 96) increase in weekly 
time in MVPA from baseline to 3 months in older adults 
which translated into a clinically significant improvement 
in cardiovascular health.17 Data clustering was not formally 
accounted for due to the lack of reference values. However, 
statistical power was increased to 90% to account for a loss 
in data independence. This study will be used to estimate 
the relatedness of data clustered at a pharmacy level, and to 
inform sample calculation for a definitive RCT.
Intervention
The intervention algorithm was developed in a prelim-
inary study (phase I). It consisted of a personalised life-
style intervention that included exercise, nutrition and 
psychosocial elements, guided by a functional and anthro-
pometric personal assessment. Men received tailored 
home-based exercise and dietary advice with a support 
pack (including an educational DVD, booklet, pedom-
eter and resistance exercise bands). Men were supported 
with two phone calls from a pharmacist and a follow-up 
appointment at 3 months after the first assessment to 
reassess goals, reinforce personalised lifestyle advice and 
support sustainability of lifestyle change. Figure 1 shows 
the study flow and elements of the intervention.
Training in how to deliver all aspects of the intervention 
was provided to pharmacy teams before the study. This 
consisted of existing modules from the Centre for Pharmacy 
Postgraduate Education (CPPE) on consultation skills and 
cardiovascular health, and a 1-day skills-based, competency 
training delivered by the research team. A team approach 
was adopted for the training and delivery of the interven-
tion. Non-pharmacist members of the team delivered the 
assessment, and pharmacists provided the lifestyle consul-
tation and advice. Therefore, each pharmacy nominated at 
least one pharmacist and at least one pharmacy technician 
or dispensing assistant (National Vocational Qualification 
level 2 or 3) to undertake the training. It was evaluated using 
a training evaluation form that was administered immedi-
ately after the training.
baseline data
Participant demographic characteristics such as age, 
ethnicity, index of multiple deprivation (IMD), type of 
cancer treatment (ie, radiotherapy or surgery) and time 
since diagnosis, whether participants had ADT, marital 
and retirement statuses, family history, comorbidities and 
Charlson Comorbidity Index (CCI) were recorded.
Primary outcome measures
The feasibility and acceptability of the intervention 
and the delivery model via community pharmacy were 
assessed. This was by evaluating study processes (rate of 
participant recruitment, consent, retention and adverse 
events), analysing delivery data, semi-structured interviews 
with participants and focus groups with pharmacy teams.
secondary outcome measures
Anthropometrics that define cardiovascular risk, such as 
weight, body mass index (BMI), waist circumference, blood 
cholesterol and blood pressure were assessed. In addi-
tion, upper-limb (grip strength45) and lower-limb (chair 
sit-to-stand46) tests were administered to classify men into 
low, medium and high strength groups (using age-specific 
cut-offs). Functional fitness was assessed with the Siconolfi 
step test47 to inform classification into low, medium and 
high groups of fitness. Self-reported physical activity was 
also assessed by Godin leisure-time exercise questionnaire 
(GLTEQ).48 These outcomes were measured at both phar-
macy visits.
Objective assessments of physical activity were 
performed with wrist-worn accelerometers (ActiWatch 
V.4.0) and used to calculate weekly time spent in MVPA 
at baseline, 3 months and 6 months, independent of the 
pharmacy assessments. Study participants received the 
device by post and were instructed to wear the ActiWatch 
continuously for 7 days, removing it only to avoid expo-
sure to water. Valid data were defined as at least 1 day of 
wear time.44 Accelerometry estimates physical activity 
levels by using short time sampling intervals (epochs). 
Standard 30 seconds epochs were used to collect the 
physical activity data and rescaled to 60 seconds epochs 
to obtain counts per minute (CPM). CPM were used in 
data analysis to calculate time spent weekly in MVPA (cut-
off ≥1041 CPM.)49 Change in MVPA was used to inform 
the sample size calculations for a future RCT.
Patient reported data were also collected. This included 
dietary intake with the Mediterranean Diet Adherence 
Screener (MEDAS) questionnaire,50Patient Activation 
Measure (PAM),51 prostate cancer-related symptoms with 
the Expanded Prostate Cancer Index Composite (EPIC-
26) tool52 and quality of life with the EQ5D-5L question-
naire.53 These data are to be reported in a subsequent 
paper. They were administered via postal questionnaires 
at baseline, 3 months (only MEDAS and PAM) and at 
6 months (study flowchart in figure 1).
 o
n
 12 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025114 on 11 June 2019. Downloaded from 
4 Lemanska A, et al. BMJ Open 2019;9:e025114. doi:10.1136/bmjopen-2018-025114
Open access 
Figure 1 Study flowchart indicating recruitment and intervention components and time points. BP, blood pressure; EPIC, 
Expanded Prostate Cancer Index Composite; EQ5D-5L, EuroQol 5 dimensions 5 levels; GP, general practitioner; MEDAS, 
Mediterranean Diet Adherence Screener; NHS, National Health Service; PAM, Patient Activation Measure.
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Process data
Information on any logistic or technical problems during 
the study were recorded, as for example, problems sched-
uling assessments or technical problems with equipment, 
web-based system or computer algorithm. The duration 
of each consultation was automatically recorded by the 
system. Service evaluation data were also captured by 
participants.
Qualitative data
Two focus groups were held with the participating phar-
macy teams at the end of the project to collect informa-
tion on the feasibility and acceptability of intervention 
components and to obtain feedback on their prepara-
tory training. This provided an opportunity to discuss 
experiences as a group of healthcare professionals across 
pharmacy teams. Semi-structured interviews with a consec-
utive sample of study participants were also conducted to 
collect the information on their overall perception and 
engagement with different intervention components. 
Six months after enrolment, 44 of the 116 participants 
were consecutively approached to take part in an inter-
view. Of these, five men declined without providing a 
reason and three declined due to the timing of the inter-
views. Thirty-six men gave written consent and 33 men 
were interviewed (in three cases, it was not possible to 
find a mutually convenient time). The focus groups and 
interviews were audio-recorded, transcribed and analysed 
thematically.
Figure 2 Consort diagram demonstrating recruitment and retention of participants throughout the study. 
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Quantitative data
Baseline patient characteristics and changes over time 
were analysed using descriptive statistics. Means and SD 
were used for normally distributed variables. Medians and 
25th and 75th percentiles were used for non-normally 
distributed variables. Frequencies and percentages were 
used for categorical variables. The significance of stan-
dardised mean differences from baseline to 3 months in 
normally distributed continuous outcome measures was 
calculated with 95% CIs. The proposed primary outcome 
measure for a future RCT was the change from baseline to 
3 months in weekly MVPA. The effect size change in this 
outcome was used to estimate sample size. An intracluster 
correlation coefficient (ICC) was calculated to account 
for the relatedness of data clustered at a pharmacy level.54
Multilevel logistic regression was used to examine the 
relationship between potential factors influencing change 
in MVPA over 3 months. A binary (yes/no) variable of 
increase in MVPA was used as a dependent variable. Phar-
macy effect was included as a random variable. Univar-
iate models were fitted with the following independent 
variables: baseline time in MVPA, age, BMI status, cancer 
treatment, ADT, marital status, IMD decile and CCI score. 
The final multivariate model was created using a back-
ward elimination procedure and statistical significance of 
p<0.1 as cut-off. Collinearity between independent vari-
ables was tested using Spearman's rank correlation coeffi-
cient r. P<0.05 was considered statistically significant. The 
data set was entered and managed in SPSS V.22. Statistical 
analyses were performed in R V.3.0.2.
Missing data and data processing
Statistical analyses were performed on all 116 study partic-
ipants who commenced the pharmacy intervention, on an 
intention to treat basis as recommended by the Consoli-
dated Standards of Reporting Trials guidelines.55 Missing 
data were imputed for 17 men who did not attend the 
second pharmacy visit, 28 who failed to provide 3-month 
ActiWatch follow-up data, and 28 men who failed to provide 
6-month ActiWatch data, using the method of last obser-
vation carried forward (LOCF).56 57 Data were imputed 
to preserve sample size and to prevent attrition bias. The 
predictable and conservative approach of LOCF was 
preferred over multiple imputation because this minimises 
the risk of overestimation of results (the effect of lifestyle 
intervention) due to data imputation.58 59 A sensitivity anal-
ysis by complete case analysis produced similar results.
Patient and public involvement
Men with prostate cancer were actively involved in the 
design and implementation of this feasibility study. 
Two volunteers, who are prostate cancer survivors, were 
involved in the codesign of the intervention resources, 
training of the community pharmacy teams and supported 
project management and governance. The study results 
were shared and consulted with the study participants 
and their families via a feedback event organised at the 
end of the study.
results
recruitment and retention
In total, 1173 health records of men with prostate cancer 
were screened and assessed for suitability, based on inclu-
sion criteria and geographic proximity to participating 
pharmacies. Study invitation letters were sent to 403 men, 
and 172 (43%) expressed interest in taking part. Of these, 
37 did not meet the inclusion criteria and 10 declined; 
125 men returned signed consent forms, but nine with-
drew before they commenced the pharmacy intervention 
(consort diagram in figure 2).
A sample of 116 men commenced the lifestyle inter-
vention. This constituted the main study cohort for all 
data analyses. This cohort had a mean age 70.4±7.2 years 
(range 50–85), of which 99 men completed the 3-month 
pharmacy intervention (15% withdrawn), 88 returned 
their 3-month ActiWatch data and 88 provided their 
6-month ActiWatch data (24% attrition rate) (figure 2).
Feasibility and acceptability of the intervention and delivery 
model
The first pharmacy assessments were delivered from June 
2016 to November 2016. The second pharmacy assessments 
were delivered between September 2016 and April 2017. 
The median time between consultations was 15 weeks. 
Community pharmacies were easy to access for men and the 
pharmacy teams had the skills and confidence to complete 
the training and deliver the intervention. The community 
pharmacy delivery was feasible for the providers and accept-
able to men with prostate cancer. This is reflected by the 
relatively small (15%) attrition of participants from the 
pharmacy intervention. In addition, 86% of men received 
1-week telephone follow-ups and 71% received 6-week 
telephone follow-ups. The number of consultations per 
pharmacy varied between 4 to 30 for the first assessment 
and 4 to 32 for the second assessment. This was primarily 
driven by the choice of participants and usually determined 
by the ease of access or proximity of a pharmacy. Due to 
staff changes and workload, some participants moved to 
another pharmacy to complete their follow-up. Pharma-
cists could pick-up those appointments and the web-based 
system enabled this transfer.
Feasibility and acceptability of outcome measures
At baseline, the average weight was 86.9±14.0 kg and 91 
(78%) men were overweight or obese using BMI (table 1). 
The average grip strength was 35.7±6.7 kg and 69 (60%) 
men were classified as having low upper-limb strength. 
The median number of chair sit-to-stands was 13 (IQR was 
10–15) and 55 (47%) men were classified as having low 
lower-limb strength. Using the Siconolfi step test 49 (42%), 
38 (33%) and 29 (25%) men were classified as having low, 
moderate and high fitness levels, respectively.
At the second pharmacy visit, upper-limb strength 
increased on average by 0.2±3.0 kg (p=0.393) and lower-
limb strength also increased significantly. Median difference 
(IQR) was 1 (0–3) chair sit-to-stands (p<0.001). Physical 
fitness did not change significantly (p=0.339). QRisk2 fell 
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significantly by 1.5% (p<0.001). The reduction in weight by 
1.0 kg (p<0.001), BMI by 0.3 kg/m3 (p<0.001), total choles-
terol by 0.4 mmol/L (p=0.004) and cholesterol ratio by 0.5 
(p<0.001) contributed to this result (online supplementary 
appendix table A1).
The three physical assessment tests (upper-limb, lower-
limb strengths and fitness) were generally acceptable and 
feasible. At baseline, one man did not attempt the sit-to-
stand test and 13 did not attempt the Siconolfi step test. At 
3 months, it was six and 22 men, respectively. The reasons 
for not participating included injuries, increased heart rate, 
dizziness, not willing to participate or technical problems 
with equipment. Siconolfi step test was used to assess men’s 
physical fitness and those who attempted it, often found it 
Table 1 Baseline demographic and anthropometric 
characteristics of the study population (n=116)
Mean (SD)
Median (Q1, 
Q3) n (%)
Age (years) 70.4 (7.2) 71 (65, 76)
  <60 9 (8)
  60–69 40 (35)
  70–79 56 (48)
  ≥80 11 (10)
Ethnicity (white) 114 (98)
Marital status (married/partner) 102 (88)
Retirement (retired) 89 (77)
Smoking status (current smoker) 2 (2)
IMD 7.5 (5, 9)
  1–3 (most deprived) 16 (14)
  4–6 24 (21)
  7–8 37 (32)
  9–10 (least deprived) 39 (34)
CCI 2 (2, 3)
  ≤2 (mild) 84 (72)
  3–4 (moderate) 16 (28)
  ≥5 (severe) 0 (0)
CCI age adjusted score 6 (5, 6)
PAM score 3 (2, 3)
  Level 1 (lowest) 15 (13)
  Level 2 16 (14)
  Level 3 58 (50)
  Level 4 (highest) 25 (22)
  Missing 2 (2)
Time since diagnosis (years) 1.5 (0.7)
  ≤1 72 (62)
  >1 36 (31)
  Missing 8 (7)
Treatment
  Surgery 49 (42)
  Radiotherapy 69 (60)
  Brachytherapy 4 (4)
  ADT 66 (57)
Number of participants per pharmacy
  A 21 (18)
  B1 9 (8)
  B2 8 (7)
  B3 9 (8)
  B4 18 (16)
  C1 30 (26)
  C2 8 (7)
  C3 4 (3)
  C4 9 (8)
Anthropometrics
Weight (kg) 86.9 (14.0)
BMI (kg/m2) 28.1 (4.1)
BMI  ≥25 kg/m2 (overweight/obese) 91 (78)
Continued
Mean (SD)
Median (Q1, 
Q3) n (%)
Waist circumference (cm) 102.8 (11.0)
Obese, waist 
circumference ≥102 cm
63 (54)
Waist-to-hip ratio 0.97 (0.06)
Waist-to-hip ratio >0.90 (obese) 101 (87)
Total cholesterol (mmol/L) 4.7 (1.3)
Cholesterol ratio 4.0 (1.3)
Systolic blood pressure (mm Hg) 134 (16)
Diastolic blood pressure (mm Hg) 81 (11)
Cardiovascular health
QRisk2 25.6 (11.3)
QRisk2 ≥20 (high risk) 83 (72)
Accelerometry data
Counts per day (1000 counts) 271 (100)
MVPA per week (min) 245 (250)
MVPA per week in ≥10 min bouts 
(min)
31 (67)
Achieving CMO guidance (N, %) 8 (7%)
Fitness and strength
Upper-limb strength (grip strength) 
(kg)
35.7 (6.7)
  Low 69 (59)
  Moderate 22 (19)
  High 25 (22)
Lower-limb strength (sit-to-stands 
in 30 seconds)
13 (10, 15)
  Low 55 (47)
  Moderate 48 (41)
  High 13 (11)
Physical fitness (Siconolfi step test)
  Low 49–42
  Moderate 38–33
  High 29–25
ADT, androgen deprivation therapy; BMI, body mass index; CCI, Charlson 
comorbidity index; CMO, chief medical office; IMD, index of multiple 
deprivation; MVPA, moderate to vigorous physical activity; PAM, patient 
activation measure; Q1, 25th percentile; Q3, 75th percentile; QRisk2, QRisk2 
2017 cardiovascular disease risk calculator (qrisk.org/2017).
Table 1 Continued 
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a useful ‘reality check’ that motivated them to make life-
style changes. However, the length of the test and the issues 
related to the small size of consultation room (‘step test too 
close to the wall’ or ‘too hot’) were identified as challenges 
for the delivery of the step test in this setting.
Assessing MVPA using accelerometry was feasible and 
acceptable to the participants. At baseline, 111 (96%) men 
provided valid ActiWatch data. The dropout rate at three 
and 6 months was 28 participants (24%). The change 
in MVPA from baseline to 3 months was the proposed 
main outcome for future evaluations of the effectiveness 
of the intervention. At baseline, men spent on average 
245±250 min in MVPA per week. This increased signifi-
cantly by 34±152 min (p=0.018) at 3 months. The statistical 
significance of the change was not sustained at 6 months 
and the average increase from baseline was 14±220 min 
(p=0.509). When counting time in bouts of ≥10 min (as 
recommended by the CMO guidance),43 only eight men 
(7%) achieved the recommended minimum of 150 min 
in MVPA per week. The standardised mean changes in 
MVPA and other outcome measures from baseline to 
3 months are presented in figure 3.
Adverse events
There were no falls or injuries reported as a direct result 
of any of the research procedures. Three participants 
were stopped from performing the Siconolfi step test for 
safety reasons because they reported dizziness during the 
pre-assessment with the physical activity readiness ques-
tionnaire.60 A further 15 participants were stopped from 
participating in the Siconolfi step test because their heart 
rate or blood pressure was above the recommended safety 
limits (85% of the age-predicted maximum heart rate, 
160 mm Hg systolic or 110 mm Hg diastolic blood pres-
sure). They were referred to their general practitioners 
and no exercise advice was provided.
Table 2 Results of multilevel logistic regression using binary (yes/no) variable of increase in MVPA as a dependent variable 
Dependant variable
Increase in MVPA (yes/no)
Yes (n=62)
No (n=54) (reference) 
Independent variables (fixed effects) Univariate model Multivariate model
Estimate Error P value Estimate Error P value 2.5% CI 97.5% CI
Time in MVPA (100 min) −0.22 0.09 0.018 −0.28 0.12 0.014 −0.529 −0.077
Age (10 years) −0.47 0.27 0.082
BMI status: normal Reference
BMI status: overweight −0.34 0.49 0.494 −0.87 0.56 0.125 −2.030 0.203
BMI status: obese −0.95 0.55 0.083 −1.72 0.66 0.009 −3.090 −0.481
Cancer treatment: radiotherapy Reference
Cancer treatment: surgery −0.74 0.38 0.052 −0.77 0.42 0.067 −1.618 −0.045
ADT: no Reference
ADT: yes 0.38 0.38 0.307
Marital status: partner Reference
Marital status: single −1.19 0.62 0.056
Employment status: unemployed/retired Reference
Employment status: working −0.47 0.44 0.286
IMD decile: 1–3 (most deprived) Reference
IMD decile: 4–6 −0.25 0.65 0.698
IMD decile: 7–8 0.02 0.60 0.973
IMD decile: 9–10 (least deprived) −0.20 0.60 0.738
CCI score: mild Reference
CCI score: moderate −0.02 0.41 0.966
Pharmacy (clustering effect) was included as a random effect. Factors that can potentially contribute to the change in MVPA over time 
were explored using univariate regression. The following independent variables were included: baseline time in MVPA (continuous), age 
(continuous), BMI status (categorical; normal, overweight, obese), cancer treatment (categorical; radiotherapy, surgery), ADT (categorical; yes, 
no), marital status (categorical; single, partner), employment status (categorical, unemployed/retired, working), IMD decile (categorical; 1–3, 
4–6, 7–8, 9–10) and CCI score (categorical; mild, moderate, severe). A backward elimination procedure and statistical significance of p<0.1 
was used to derive a final multivariate model. P<0.05 was considered statistically significant. ADT, androgen deprivation therapy; BMI, body 
mass index; CCI, Charlson Comorbidity Index; IMD, index of multiple deprivation; MVPA, moderate to vigorous physical activity.
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Factors that influence change in physical activity
Age did not influence the change in MVPA from base-
line to 3 months (p=0.548) (table 2). The main predic-
tors of increase in MVPA were the baseline time in MVPA 
(p=0.027) and the BMI status (p=0.008). The increase in 
MVPA was inversely associated with the amount of MVPA 
at baseline, so the more MVPA men did at baseline, the 
less likely it was to improve at 3 months. In addition, 
obese men were less likely to increase their MVPA than 
men with normal BMI.
sample size for a future rCt
The change in weekly time spent in MVPA from baseline 
to 3 months is the proposed primary outcome used for 
the calculation of sample size. The ICC for the change in 
MVPA from baseline to 3 months was 0.04 (95% CI −0.03 
to 0.28) and the effect size for paired data was estimated as 
0.22 (95% CI −0.04 to 0.48), which by thresholds defined 
by Jacob,61 represented a small effect size. To achieve 80% 
power at a two-tailed significance level of 0.05, a sample 
size of 632 men would be required to demonstrate the 
effectiveness of this lifestyle intervention at 3 months in a 
future RCT. Further adjustment for the loss of statistical 
power due to a clustering of data,54 and allowance for an 
estimated 25% attrition, increases this to 1202 men.
DIsCussIOn
Feasibility and acceptability of the intervention
This is the first study to test the feasibility and acceptability 
of a community pharmacy lifestyle intervention for men 
with prostate cancer in preparation for an RCT. Overall, 
the design was found to be feasible and the intervention 
acceptable to both providers and men living beyond a 
diagnosis of prostate cancer.
The results of this study confirm that a community phar-
macy lifestyle intervention is acceptable to men living with 
and beyond cancer. The study also demonstrates that it 
is feasible to deliver the intervention in three different 
commercial community pharmacy models. A strength of 
the recruitment strategy was that the invitation letters were 
sent via oncology consultants. There is evidence that physi-
cian-prompting improves recruitment to clinical trials.62 63 
In addition, studies show that individuals participate in clin-
ical research for altruistic reasons.64 Men who participated 
were not only keen to improve their health and fitness, but 
also keen to contribute towards improving future support 
for other men after treatment. The main reasons for 
non-participation were too busy, unwell or already phys-
ically active. This increased understanding of facilitators 
and barriers to participation will be used in the planning of 
a successful recruitment strategy for a future trial.
Figure 3 Standardised mean changes in outcome measures from baseline to 3 months. All significant changes are in a 
favourable direction and are marked in red. BMI, body mass index; BP, blood pressure; MVPA, moderate to vigorous physical 
activity; QRisk2, QRisk2 2017 cardiovascular disease risk calculator (qrisk.org/2017).
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Given that prostate cancer survivorship is frequently 
accompanied by comorbid conditions and an increased 
risk of cardio-metabolic disease,14 15 community-based 
provision of lifestyle advice could have far-reaching impli-
cations for future health and quality of life in this patient 
group. However, the effectiveness of this model may 
depend on better communication between primary and 
secondary care. Qualitative data from participant inter-
views and focus groups with pharmacy teams revealed 
that the participants wrongly assumed that pharma-
cists had access to their NHS hospital and primary care 
records. A number of challenges due to the poor infor-
mation exchange between primary and secondary sectors 
have been identified in the literature,65 suggesting a 
limited ability to provide a continuum of care and lack 
of a coordinated approach to managing comorbidities. 
Patients often report unmet information and support 
needs during and after treatment.66 67 This community 
pharmacy model could be used as a platform for reducing 
unmet health needs and in ensuring a more seamless 
transition from oncology services to primary care support 
during and beyond prostate cancer treatment.
Informing a design of a definitive rCt
The potential benefits of lifestyle interventions in prostate 
cancer survivors include decreased disease recurrence 
and improvements in quality of life, fatigue and physical 
function.68 However, a systematic review of exercise inter-
ventions has shown that it is unrealistic for the majority of 
older sedentary men in UK to achieve the exercise levels 
recommended by the CMO guidelines.69 This was also 
true in our study where only 7% of men achieved it. While 
this study provides evidence of the potential to improve 
physical activity and reduce health risks of men with pros-
tate cancer, there needs to be more consideration of how 
to sustain lifestyle changes long term. In our study, the 
increase in physical activity at 6 months, fell from the 
statistically significant increase level at 3 months.
The 7% of men achieving CMO guidelines, reported 
here, was lower than the 12% reported for cancer patients 
in Galvao et al70 and lower than the 38% reported for 
older adults in UK population.71 This may be due to the 
recruitment bias resulting from targeting men with low 
physical activity levels and pre-existing cardiovascular risk 
factors, including obesity. Men with higher MVPA levels 
at baseline showed no improvement in MVPA over the 
course of the study. In addition, obesity was identified as a 
barrier to increasing MVPA. Although these men were not 
achieving recommended MVPA levels, they were poten-
tially able to increase physical activity, for example via the 
leisure-time exercise (such as walking or gardening). This 
still provides health benefits but may not be captured 
by accelerometery and therefore under-reported in the 
MVPA outcome. Age-specific accelerometer cut-offs have 
been devised by Rejeski et al72 and should be used to 
increase the sensitivity of physical activity intensity classifi-
cations, personalised advice and to improve the potential 
for capturing clinically meaningful improvements.
In this respect, the extent to which current CMO phys-
ical activity guidelines are appropriate for older prostate 
cancer patients is unknown. They may be unrealistic 
in terms of what older or obese cancer survivors can 
achieve. We therefore suggest, that lifestyle advice should 
be tailored to age, weight and individual capabilities, 
including the setting of realistic goals,73 with the ultimate 
aim of achieving (or exceeding) CMO recommendations. 
Overweight and obese men were a significant proportion 
(78%) of the sample and they were less likely to improve 
their MVPA. They may potentially benefit from a tailored 
or stepped approach to weight loss during or prior the 
exercise intervention. In addition, the results show that 
the significant increase in MVPA at 3 months was not 
sustained over 6 months. Therefore, to maintain adher-
ence and realise long-term benefits, it would be beneficial 
to consider how maintenance can be enhanced through 
behavioural change techniques for future evaluations of 
this intervention.
strengths and limitations
The recruitment approach was a clear strength of this 
study. The results demonstrate that an invitation from 
an oncology consultant is helpful in promoting interest 
in lifestyle intervention research. Another strength was 
that participating pharmacies were drawn from different 
business models, ensuring that the findings are repre-
sentative across the sector. The intervention effect size 
and pharmacy clustering effect were calculated and this 
can be used to estimate the sample size for a future RCT. 
This is a strength, because to our knowledge there is no 
other research to provide this information. While the 
intervention was limited to one geographic location, the 
individual pharmacies were selected to provide socio-
economic diversity and mixture of urban and semi-rural 
settings that were representative of a wider area.
The intervention was built on a web-based platform 
that is used each year by more than 87% of the 11 700 
community pharmacies in England, and more than 
26 000 different providers in the UK. This was to ensure 
that the intervention would be flexible with regard to a 
geographic location and that it was feasible to rapidly 
scale-up. The use of accelerometery for the proposed 
primary outcome measure is a strength because it 
provides an objective evaluation of physical activity. Infor-
mation about frequency, intensity and duration (time) 
of exercise can be obtained. However, accelerometery 
provides limited information, in particular about the type 
of physical activity. This is important to consider in light 
of the frequency, intensity, time and type (FITT) prin-
ciple.74 With an older population, individuals often get 
exercise via activities of daily living or leisure (eg, walking 
or gardening). Therefore, to explore the adherence to 
exercise interventions, the objective measures such as 
accelerometery should not be used alone. Here, leisure-
time physical activity was assessed using the self-reported 
GLTEQ. Upper-limb and lower-limb strengths were also 
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assessed to objectively capture the potential changes due 
to the prescribed resistance training.
In addition, analysis of men’s perceptions and adher-
ence to the intervention were also conducted using qual-
itative interviews. This was to capture the utilisation of 
resistance exercise bands and adherence to the strength 
training element of the intervention. This is important 
for the functional strength of men but is not captured 
by accelerometery. An original version of the validated 
GLTEQ48 was used in this study. It is a tool used inter-
nationally in oncology research to evaluate exercise 
interventions or assess a relative change in total exercise 
behaviour.75 However, item content of the GLTEQ may 
lead to under-reporting of resistance training activities, 
such as those using resistance bands. Adapted GLTEQ 
versions designed to capture the resistance training have 
been reported.76 77
This feasibility study did not test randomisation of 
participants. This was guided by a requirement from the 
funder that the intervention was provided to all partic-
ipants. This is a limitation and will require further user 
involvement and consultations to explore feasibility and 
acceptability prior to a future RCT. The lack of ethnic 
variability is a limitation. The majority of our sample are 
white men, so we did not explore ethnic differences in 
feasibility and acceptability. To remedy this in a future 
trial, recruitment needs to take place in areas with higher 
rates of ethnic minorities.
COnClusIOns
This study shows that community pharmacies could have 
an important role in supporting cancer survivorship 
initiatives in primary care, providing accessible, person-
alised lifestyle interventions in the high street. New 
evidence is provided for the potential of pharmacy-led 
lifestyle interventions to benefit the health of men living 
with and beyond prostate cancer. The algorithm and the 
fitness assessment require further refinement to be more 
practical in the pharmacy setting. However, the prelimi-
nary results are promising. Men were shown to improve 
physical activity, other lifestyle factors, and cardiovascular 
risk score. They may need more support to maintain such 
benefits in the long-term. This study is an essential step 
towards an RCT to evaluate the effectiveness and cost-ef-
fectiveness of this community pharmacy lifestyle interven-
tion for men with prostate cancer.
Author affiliations
1School of Health Sciences, Faculty of Health and Medical Sciences, University of 
Surrey, Guildford, UK
2Department of Nutritional Sciences, Faculty of Health and Medical Sciences, 
University of Surrey, Guildford, UK
3School of Biosciences and Medicine, Faculty of Health and Medical Sciences, 
University of Surrey, Guildford, UK
4Department of Sport, Exercise and Rehabilitation, Northumbria University, 
Newcastle upon Tyne, UK
5Frimley Health NHS Foundation Trust, Frimley, UK
6Surrey Human Performance Institute, University of Surrey, Guildford, UK
Acknowledgements We thank men and their families for their participation and 
contribution to the project. We thank clinicians at the Portsmouth Hospitals NHS 
Trust for their help recruiting participants and Lloyds Pharmacy Ltd, Rowlands 
Pharmacy Ltd and City Pharmacy organisations and staff for participating in the 
study. We thank all members of the Study Advisory Committee for their contribution 
and their advisory role on the project: John Heyworth and John Marshall, Patient 
and Public Involvement, Prostate Cancer UK; Sally Greensmith, Centre for Pharmacy 
Postgraduate Education, University of Manchester; Zachariah Nazar, University of 
Portsmouth; Graham Phillips, Manor Pharmacy Group, Herts; Gary Warner and Kevin 
Noble, PharmOutcomes, Pinnacle Health Partnership LLP. Fiona Archer and Sophie 
Gasson are thanked for leading data collection and data entry aspects. 
Contributors AL, KP and SF drafted most of this manuscript. All authors 
contributed to the manuscript, data analysis and interpretation. SF was Principal 
Investigator. AL coordinated engagement with community pharmacies, implemented 
the web-based algorithm and was a lead author. KP was the project manager and 
coordinated ethical approvals. JS, RM and JW supported the project with expertise 
in exercise physiology. BG and LT provided expertise in nutrition.
Funding This study (NIHR/UKCRN ID 20874) was funded by the Movember 
Foundation, in partnership with Prostate Cancer UK, as part of the global True 
NTH programme, grant number 250-20 and was supported by the NIHR Clinical 
Research Network. 
Competing interests SF is a trustee of Prostate Cancer UK. All other authors 
declare that they have no competing interests. 
Patient consent for publication Obtained.
ethics approval The NHS Health Research Authority South Central-Berkshire B 
Research Ethics Committee gave a favourable ethical opinion for this study (16/
SC/0069). Research governance assurance was provided by Wessex Primary Care 
Research Support Service (IRAS ID 193263, 4 April 2016) and permission gained 
from each community pharmacy contractor hosting the study. 
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Data from this study are available on request.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
reFerenCes
 1. Maddams J, Utley M, Møller H. Projections of cancer prevalence in 
the United Kingdom, 2010-2040. Br J Cancer 2012;107:1195–202.
 2. Gavin AT, Drummond FJ, Donnelly C, et al. Patient-reported ‘ever 
had’ and ‘current’ long-term physical symptoms after prostate 
cancer treatments. BJU Int 2015;116:397–406.
 3. Ross KM, Ranby KW, Wooldridge JS, et al. Effects of physical and 
mental health on relationship satisfaction: a dyadic, longitudinal 
examination of couples facing prostate cancer. Psychooncology 
2016;25:898–904.
 4. Drummond FJ, Kinnear H, O'Leary E, et al. Long-term health-
related quality of life of prostate cancer survivors varies by primary 
treatment. Results from the PiCTure (Prostate Cancer Treatment, your 
experience) study. J Cancer Surviv 2015;9:361–72.
 5. Zajdlewicz L, Hyde MK, Lepore SJ, et al. Health-related quality of life 
after the diagnosis of locally advanced or advanced prostate cancer: 
A longitudinal study. Cancer Nurs 2017;40:412–9.
 6. Kerleau C, Guizard AV, Daubisse-Marliac L, et al. Long-term 
quality of life among localised prostate cancer survivors: QALIPRO 
population-based study. Eur J Cancer 2016;63:143–53.
 7. Chambers SK, Sk N, Baade P, et al. Trajectories of quality of life, life 
satisfaction, and psychological adjustment after prostate cancer. 
Psycho-Oncology 2016.
 8. Teleni L, Chan R, Chan A, et al. Dietary and exercise interventions to 
improve quality oflife, metabolic risk factors and androgen deficiency 
symptoms in men with prostate cancer undergoing androgen 
deprivation therapy. Supportive Care in Cancer 2015;23:S171.
 9. Teleni L, Chan RJ, Chan A, et al. Exercise improves quality of life in 
androgen deprivation therapy-treated prostate cancer: systematic 
review of randomised controlled trials. Endocr Relat Cancer 
2016;23:101–12.
 o
n
 12 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025114 on 11 June 2019. Downloaded from 
12 Lemanska A, et al. BMJ Open 2019;9:e025114. doi:10.1136/bmjopen-2018-025114
Open access 
 10. Fraser S, Gardner J, Livingston P. The effects of exercise on 
treatment side effects for prostate cancer patients receiving 
androgen deprivation therapy: A systematic review. BJU international 
2013;112 http:// onlinelibrary. wiley. com/ o/ cochrane/ clcentral/ articles/ 
913/ CN- 01006913/ frame. html.
 11. Gardner JR, Livingston PM, Fraser SF. Effects of exercise on 
treatment-related adverse effects for patients with prostate cancer 
receiving androgen-deprivation therapy: a systematic review. J Clin 
Oncol 2014;32:335–46.
 12. Taaffe DR, Newton RU, Spry N, et al. Effects of different exercise 
modalities on fatigue in prostate cancer patients undergoing 
androgen deprivation therapy: A year-long randomised controlled 
trial. Eur Urol 2017;72:293–9.
 13. Wall BA, Galvão DA, Fatehee N, et al. Exercise improves 
V[Combining Dot Above]O 2max and body composition in ADT-
treated prostate cancer patients. Medicine And Science In Sports 
And Exercise 2017.
 14. Weaver KE, Foraker RE, Alfano CM, et al. Cardiovascular risk factors 
among long-term survivors of breast, prostate, colorectal, and 
gynecologic cancers: a gap in survivorship care? J Cancer Surviv 
2013;7:253–61.
 15. Leach CR, Weaver KE, Aziz NM, et al. The complex health profile of 
long-term cancer survivors: prevalence and predictors of comorbid 
conditions. Journal of Cancer Survivorship 2015;9:239–51.
 16. NICE. Prostate cancer Quality standard (QS91). Published 2015;11 
www. nice. org. uk/ guidance/ qs91.
 17 Kenfield SA, Stampfer MJ, Giovannucci E, et al. Physical activity and 
survival after prostate cancer diagnosis in the health professionals 
follow-up study. J Clin Oncol 2011;29:726–32.
 18. Bonn SE, Sjolander A, Lagerros YT, et al. Physical activity and 
survival among men diagnosed with prostate cancer. Cancer 
Epidemiology Biomarkers & Prevention 2015;24:57–64.
 19. Friedenreich CM, Wang Q, Neilson HK, et al. Physical Activity and 
Survival After Prostate Cancer. Eur Urol 2016;70:576–85.
 20. Westerink NL, Nuver J, Lefrandt JD, et al. Cancer treatment induced 
metabolic syndrome: Improving outcome with lifestyle. Crit Rev 
Oncol Hematol 2016;108:128–36.
 21. Fisher A, Williams K, Beeken R, et al. Recall of physical activity 
advice was associated with higher levels of physical activity in 
colorectal cancer patients. BMJ Open 2015;5:e006853.
 22. Fisher A, Wardle J, Beeken RJ, et al. Perceived barriers and benefits 
to physical activity in colorectal cancer patients. Support Care 
Cancer 2016;24:903–10.
 23. Park JH, Lee J, Oh M, et al. The effect of oncologists' exercise 
recommendations on the level of exercise and quality of life in 
survivors of breast and colorectal cancer: A randomized controlled 
trial. Cancer 2015;121:2740–8.
 24. Haussmann A, Gabrian M, Ungar N, et al. What hinders healthcare 
professionals in promoting physical activity towards cancer patients? 
The influencing role of healthcare professionals' concerns, perceived 
patient characteristics and perceived structural factors. Eur J Cancer 
Care 2018;27:e12853.
 25. Tsiouris A, Ungar N, Haussmann A, et al. Health Care Professionals' 
Perception of Contraindications for Physical Activity During Cancer 
Treatment. Front Oncol 2018;8:98.
 26. Rubin G, Berendsen A, Crawford SM, et al. The expanding role of 
primary care in cancer control. Lancet Oncol 2015;16:1231–72.
 27. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of 
diagnoses in the General Practice Research Database: a systematic 
review. Br J Clin Pharmacol 2010;69:4–14.
 28. Faithfull S, Lemanska A, Aslet P, et al. Integrative review on the 
non-invasive management of lower urinary tract symptoms in 
men following treatments for pelvic malignancies. Int J Clin Pract 
2015;69:1184–208.
 29. Owen PJ, Daly RM, Livingston PM, et al. Lifestyle guidelines for 
managing adverse effects on bone health and body composition in 
men treated with androgen deprivation therapy for prostate cancer: 
an update. Prostate Cancer Prostatic Dis 2017;20:137–45.
 30. Mackridge AJ, Gray NJ, Krska J. A cross-sectional study using 
freedom of information requests to evaluate variation in local 
authority commissioning of community pharmacy public health 
services in England. BMJ Open 2017;7:e015511.
 31. George PP, Molina JA, Cheah J, et al. The evolving role of the 
community pharmacist in chronic disease management - a literature 
review. Ann Acad Med Singapore 2010;39:861–7.
 32. Brown D, Portlock J, Rutter P, et al. From community pharmacy to 
healthy living pharmacy: positive early experiences from Portsmouth, 
England. Res Social Adm Pharm 2014;10:72–87.
 33. Atkins K, van Hoek AJ, Watson C, et al. Seasonal influenza 
vaccination delivery through community pharmacists in England: 
evaluation of the London pilot. BMJ Open 2016;6:e009739.
 34. Cormie P, Galvão DA, Spry N, et al. Can supervised exercise 
prevent treatment toxicity in patients with prostate cancer initiating 
androgen-deprivation therapy: a randomised controlled trial. BJU Int 
2015;115:256–66.
 35. Galvao DA, Spry N, Taaffe DR, et al. Effects of exercise on 
cardiometabolic profile of prostate cancer survivors from radar: 
A multicentre randomized trial. Supportive Care in Cancer 
2012;20:S105.
 36. Kiwata JL, Dorff TB, Schroeder ET, et al. A review of clinical effects 
associated with metabolic syndrome and exercise in prostate cancer 
patients. Prostate Cancer Prostatic Dis 2016;19:323–32.
 37. Bourke L, Doll H, Crank H, et al. Lifestyle intervention in men with 
advanced prostate cancer receiving androgen suppression therapy: a 
feasibility study. Cancer Epidemiol Biomarkers Prev 2011;20:647–57.
 38. Mutrie N, Doolin O, Fitzsimons CF, et al. Increasing older adults' 
walking through primary care: results of a pilot randomized controlled 
trial. Fam Pract 2012;29:633–42.
 39. Medina-Perucha L, Yousaf O, Hunter MS, et al. Barriers to medical 
help-seeking among older men with prostate cancer. J Psychosoc 
Oncol 2017;35:531–43.
 40. Neal RD. NICE prostate cancer clinical guideline: implications for 
primary care. Br J Gen Pract 2008;58:607–8.
 41. Tueller SJ, Van Dorn RA, Bobashev GV. Visualization of categorical 
longitudinal and times series data. Methods Rep RTI Press 
2016;2016. MR-0033-1602.
 42. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating 
complex interventions: the new Medical Research Council guidance. 
BMJ 2008;337:a1655.
 43. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure 
of lower body strength in community-residing older adults. Res Q 
Exerc Sport 1999;70:113–9.
 44. Harris T, Kerry SM, Victor CR, et al. A primary care nurse-delivered 
walking intervention in older adults: PACE (pedometer accelerometer 
consultation evaluation)-Lift cluster randomised controlled trial. PLoS 
Med 2015;12:e1001783.
 45. Lauretani F, Russo CR, Bandinelli S, et al. Age-associated changes 
in skeletal muscles and their effect on mobility: an operational 
diagnosis of sarcopenia. J Appl Physiol 2003;95:1851–60.
 46. Rikli RE, Jones CJ. Functional Fitness Normative Scores for 
Community-Residing Older Adults, Ages 60-94. J Aging Phys Act 
1999;7:162–81.
 47. Siconolfi SF, Garber CE, Lasater TM, et al. A simple, valid step test 
for estimating maximal oxygen uptake in epidemiologic studies. Am 
J Epidemiol 1985;121:382–90.
 48. Godin G, Shephard RJ. A simple method to assess exercise behavior 
in the community. Can J Appl Sport Sci 1985;10:141–6.
 49. Copeland JL, Esliger DW. Accelerometer assessment of 
physical activity in active, healthy older adults. J Aging Phys Act 
2009;17:17–30.
 50. Schröder H, Fitó M, Estruch R, et al. A short screener is valid for 
assessing Mediterranean diet adherence among older Spanish men 
and women. J Nutr 2011;141:1140–5.
 51. Hibbard JH, Stockard J, Mahoney ER, et al. Development of the 
Patient Activation Measure (PAM): conceptualizing and measuring 
activation in patients and consumers. Health Serv Res 2004;39(4 Pt 
1):1005–26.
 52. Szymanski KM, Wei JT, Dunn RL, et al. Development and validation 
of an abbreviated version of the expanded prostate cancer index 
composite instrument for measuring health-related quality of life 
among prostate cancer survivors. Urology 2010;76:1245–50.
 53. Rabin R, de Charro F. EQ-5D: a measure of health status from the 
EuroQol Group. Ann Med 2001;33:337–43.
 54. Killip S, Mahfoud Z, Pearce K. What is an intracluster correlation 
coefficient? Crucial concepts for primary care researchers. Ann Fam 
Med 2004;2:204–8.
 55. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting 
of pragmatic trials: an extension of the CONSORT statement. BMJ 
2008;337:a2390.
 56. Dossing A, Tarp S, Furst DE, et al. Interpreting trial results following 
use of different intention-to-treat approaches for preventing 
attrition bias: a meta-epidemiological study protocol. BMJ Open 
2014;4:e005297.
 57. Del Re AC, Maisel NC, Blodgett JC, et al. Intention-to-treat analyses 
and missing data approaches in pharmacotherapy trials for alcohol 
use disorders. BMJ Open 2013;3:e003464.
 58. Wright CC, Sim J. Intention-to-treat approach to data from 
randomized controlled trials: a sensitivity analysis. J Clin Epidemiol 
2003;56:833–42.
 59. Papp KA, Fonjallaz P, Casset-Semanaz F, et al. Approaches to 
reporting long-term data. Current medical research and opinion 
2008;24:2001–8.
 o
n
 12 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025114 on 11 June 2019. Downloaded from 
13Lemanska A, et al. BMJ Open 2019;9:e025114. doi:10.1136/bmjopen-2018-025114
Open access
 60. Shephard RJ. PAR-Q, Canadian home fitness test and exercise 
screening alternatives. Sports Med 1988;5:185–95.
 61. Jacob C. Statistical Power Analysis for the Behavioral Sciences. 2nd 
Edn. New York, USA: edLawrence Erlbaum Associates, 1988.
 62. Carter A, Humphreys L, Snowdon N, et al. Participant recruitment 
into a randomised controlled trial of exercise therapy for people with 
multiple sclerosis. Trials 2015;16:468.
 63. Lindblad AS, Zingeser P, Sismanyazici-Navaie N. Incentives and 
barriers to neurological clinical research participation. Clin Investig 
2011;1:1663–8.
 64. Newington L, Metcalfe A. Factors influencing recruitment to research: 
qualitative study of the experiences and perceptions of research 
teams. BMC Med Res Methodol 2014;14:10.
 65. Sussman J, Baldwin LM. The interface of primary and oncology 
specialty care: from diagnosis through primary treatment. J Natl 
Cancer Inst Monogr 2010;2010:18–24.
 66. Pai H, Bender J, Tong C, et al. 196: What are the unmet information 
and supportive care needs of canadian prostate cancer patients?. 
Radiotherapy and Oncology 2016;120:S72.
 67. Watson E, Shinkins B, Frith E, et al. Symptoms, unmet needs, 
psychological well-being and health status in survivors of 
prostate cancer: implications for redesigning follow-up. BJU Int 
2016;117:E10–E19.
 68. Bourke L, Smith D, Steed L, et al. Exercise for Men with Prostate 
Cancer: A Systematic Review and Meta-analysis. Eur Urol 
2016;69:693–703.
 69. Bourke L, Homer KE, Thaha MA, et al. Interventions to improve 
exercise behaviour in sedentary people living with and beyond 
cancer: a systematic review. Br J Cancer 2014;110:831–41.
 70. Galvão DA, Newton RU, Gardiner RA, et al. Compliance to exercise-
oncology guidelines in prostate cancer survivors and associations 
with psychological distress, unmet supportive care needs, and 
quality of life. Psychooncology 2015;24:1241–9.
 71. . Public Health England (PHE): Physical Activity. 2018 https:// 
fingertips. phe. org. uk/ profile/ physical- activity (Accessed June 2018).
 72. Rejeski WJ, Marsh AP, Brubaker PH, et al. Analysis and interpretation 
of accelerometry data in older adults: The LIFE study. J Gerontol A 
Biol Sci Med Sci 2016;71:521–8.
 73. O'Donovan G, Blazevich AJ, Boreham C, et al. The ABC of physical 
activity for health: a consensus statement from the british association 
of sport and exercise sciences. J Sports Sci 2010;28:573–91.
 74. Barisic A, Leatherdale ST, Kreiger N. Importance of frequency, 
intensity, time and type (FITT) in physical activity assessment for 
epidemiological research. Can J Public Health 2011;102:174–5.
 75. Amireault S, Godin G, Lacombe J, et al. The use of the godin-
shephard leisure-time physical activity questionnaire in oncology 
research: A systematic review. BMC Med Res Methodol 2015;15:60.
 76. Lubans DR, Plotnikoff RC, Jung M, et al. Testing mediator variables 
in a resistance training intervention for obese adults with type 2 
diabetes. Psychol Health 2012;27:1388–404.
 77. Short CE, James EL, Girgis A, et al. Move more for life: the protocol 
for a randomised efficacy trial of a tailored-print physical activity 
intervention for post-treatment breast cancer survivors. BMC Cancer 
2012;12:172.
 o
n
 12 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025114 on 11 June 2019. Downloaded from 
